BeiGene Ltd (SHSE:688235)
Â¥ 133.37 1.74 (1.32%) Market Cap: 134.50 Bil Enterprise Value: 122.01 Bil PE Ratio: 0 PB Ratio: 5.37 GF Score: 55/100

Beigene Ltd to Discuss the Company's Early Development Pipeline and Research Call Transcript

Jul 09, 2020 / 01:00PM GMT
Craig West
BeiGene, Ltd. - Senior Director of IR

Hello, everyone, and welcome to BeiGene's Early Development Pipeline and Research Virtual Event. My name is Craig West, and I'm the Head of Investor Relations at BeiGene. We have the great pleasure of having with us today both of BeiGene's Co-founders, Dr. Xiaodong Wang and John Oyler.

In addition to being founders of BeiGene, Dr. Wang is the Chairman of our scientific advisory board, and John Oyler is BeiGene's Chairman and CEO. In addition, we have Dr. Lai Wang, Senior Vice President, Head of Global Research and APAC Clinical Development; Dr. Eric Hedrick, BeiGene's Chief Adviser. And in addition, during the Q&A, we'll have Dr. Jane Huang, CMO of Hematology and Dr. Yong Ben, CMO of Immuno-Oncology; Dr. Howard Liang, CFO and Chief Strategy Officer, will be our host for today. After the presentations, we'll take questions from the audience. (Operator Instructions) As a reminder, today's call will be recorded.

I would now like to introduce your host for today's conference, Howard Liang. Howard, let me turn the call over to you.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot